Author:
Cicero Julien,Trouvilliez Sarah,Palma Martine,Ternier Gaetan,Decoster Laurine,Happernegg Eloise,Barois Nicolas,Van Outryve Alexandre,Dehouck Lucie,Bourette Roland P.,Adriaenssens Eric,Lagadec Chann,Tarhan Cagatay Mehmet,Collard Dominique,Souguir Zied,Vandenhaute Elodie,Maubon Grégory,Sipieter François,Borghi Nicolas,Shimizu Fumitaka,Kanda Takashi,Giacobini Paolo,Gosselet Fabien,Maubon Nathalie,Le Bourhis Xuefen,Van Seuningen Isabelle,Mysiorek Caroline,Toillon Robert-Alain
Abstract
Abstract
Background
Triple-Negative Breast Cancer is particularly aggressive, and its metastasis to the brain has a significant psychological impact on patients' quality of life, in addition to reducing survival. The development of brain metastases is particularly harmful in triple-negative breast cancer (TNBC). To date, the mechanisms that induce brain metastasis in TNBC are poorly understood.
Methods
Using a human blood–brain barrier (BBB) in vitro model, an in vitro 3D organotypic extracellular matrix, an ex vivo mouse brain slices co-culture and in an in vivo xenograft experiment, key step of brain metastasis were recapitulated to study TNBC behaviors.
Results
In this study, we demonstrated for the first time the involvement of the precursor of Nerve Growth Factor (proNGF) in the development of brain metastasis. More importantly, our results showed that proNGF acts through TrkA independent of its phosphorylation to induce brain metastasis in TNBC. In addition, we found that proNGF induces BBB transmigration through the TrkA/EphA2 signaling complex. More importantly, our results showed that combinatorial inhibition of TrkA and EphA2 decreased TBNC brain metastasis in a preclinical model.
Conclusions
These disruptive findings provide new insights into the mechanisms underlying brain metastasis with proNGF as a driver of brain metastasis of TNBC and identify TrkA/EphA2 complex as a potential therapeutic target.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology